Using a humanized immunotherapy model of EGFR-resistant NSCLC, we elucidated that ILT4 inhibition could be used as the second-line therapy in EGFR mutant patients who acquire resistance to EGFR-TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.